Ask me how   

Mayo Clinic Laboratories can optimize your lab’s financial performance

With dozens of clinically available inflammatory bowel disease testing options, choosing the right test for your patients can be complicated, costly, and confusing. 

Mayo Clinic Laboratories’ expert-backed menu of inflammatory bowel disease testing is supported by a team of gastrointestinal disease specialists who can provide information and tactics to:

  • Improve your test utilization.
  • Decrease your testing costs.
  • Achieve better test results for your patients.

Customized insights for improved outcomes

Our GI experts are available to help you better understand your IBD test utilization and highlight potential cost savings through our customizable cost calculator.

Schedule your consultation today.

By the numbers

3 Million

3 million Americans1 and 6 million to 8 million individuals globally2 have IBD

$31 Billion

$31 billion annual financial burden of IBD3 in the U.S.

3.9 Million

3.9 million prescriptions written for medications to treat IBD in 2010

More IBD resources

A new path forward: Hussein
May 2, 2022

For a young child diagnosed with inflammatory bowel disease, an unexpected turn of events led by results of a Mayo Clinic Laboratories test freed him and his family from the bonds of frequent medical visits and expensive treatment, and opened the door to a life unencumbered by illness.

Inflammatory Bowel Disease: IBDP2 [Test in Focus]
April 19, 2022

In this “Test in Focus” episode of the  "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
Genetic Testing for Early Onset Inflammatory Bowel Disease [Test In Focus]
February 5, 2019

Ann Moyer, M.D., Ph.D., gives an overview of the inflammatory bowel disease primary immunodeficiency testing available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

References

  1. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years — United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;(65):1166–1169. 
  2. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet Gastroenterol Hepatol. 2020;5(1):17-30.
  3. Terlizzi EP, Dahlhamer JM, Xu F, Wheaton AG, Greenlund KJ. Health care utilization among U.S. adults with inflammatory bowel disease, 2015–2016. Natl Stat Health Report. Feb. 2021;(152)1-7.